Anti-CXCR4 Single-Chain Variable Fragment Antibodies Have Anti-Tumor Activity

| PedroPedro | 0 Comment
Anti-CXCR4 Single-Chain Variable Fragment Antibodies Have Anti-Tumor Activity post thumbnail image
Monoclonal antibodies (mAbs) are massive and have limitations as most cancers therapeutics. Human single-chain variable fragment (scFv) is a small antibody as various. It may simply enter most cancers tissues, has no immunogenicity and might be produced in micro organism to lower the price. The chemokine receptor CXCR4 is overexpressed in numerous most cancers cells.
It performs an necessary position in tumor development and metastasis. Its overexpression is related to poor prognosis in most cancers sufferers and is considered a lovely goal for most cancers therapy. On this examine, a peptide on the CXCR4 extracellular loop 2 was used as an antigen for screening a human scFv antibody library by yeast two-hybrid technique.
Three anti-CXCR4 scFv antibodies have been remoted. They might bind to CXCR4 protein and three most cancers cell traces and to not 293T and 3T3 cells as destructive controls. These three scFvs might lower the proliferation, migration, and invasion of those most cancers cells and promote their apoptosis. The 2 scFvs have been additional examined in a mouse xenograft mannequin, and so they inhibited the tumor development.
Tumor immunohistochemistry additionally demonstrated that the 2 scFvs decreased most cancers cell proliferation and tumor angiogenesis and elevated their apoptosis. These outcomes present that these anti-CXCR4 scFvs can lower most cancers cell proliferation and inhibit tumor development in mice, and should present remedy for varied cancers.

Microtiter plate-based antibody-competition assay to find out binding affinities and plasma/blood stability of CXCR4 ligands

C-X-C chemokine receptor kind 4 (CXCR4) is concerned in a number of intractable illness processes, together with HIV an infection, most cancers cell metastasis, leukemia cell development, rheumatoid arthritis, bronchial asthma and pulmonary fibrosis. Thus, CXCR4 represents a promising drug goal and several other CXCR4 antagonizing brokers are in preclinical or scientific improvement.
Necessary parameters in drug lead analysis are willpower of binding affinities to the receptor and evaluation of their stability and exercise in plasma or blood of animals and people. Right here, we designed a microtiter plate-based CXCR4 antibody competitors assay that permits to measure inhibitory concentrations (IC50 values) and affinity constants (Okayi values) of CXCR4 concentrating on medication.
The assay is predicated on the remark that the majority if not all CXCR4 antagonists compete with binding of the fluorescence-tagged CXCR4 antibody 12G5 to the receptor. We reveal that this antibody-competition assay permits a handy and low cost willpower of binding affinities of varied CXCR4 antagonists in residing cells inside simply three h.
Furthermore, the assay might be carried out within the presence of excessive concentrations of physiologically related physique fluids, and thus is a helpful readout to judge stability (i.e. half-life) of CXCR4 ligands in serum/plasma, and even entire human and mouse blood ex vivo.
Thus, this optimized 12G5 antibody-competition assay permits a strong and handy willpower and calculation of varied necessary
pharmacological parameters of CXCR4 receptor-drug interplay and should not solely foster future drug improvement but in addition animal welfare by decreasing the variety of experimental animals.

Anti-CXCR4 Antibody Mixed With Activated and Expanded Pure Killer Cells for Sarcoma Immunotherapy.

Sarcoma is without doubt one of the most extreme types of pediatric most cancers and present therapies -chemotherapy and surgery- fail to eradicate the illness in half of sufferers. Preclinical research combining new therapeutic approaches might be helpful to design higher therapies.
On one hand, it’s recognized that CXCR4 expression is implicated in rhabdomyosarcoma development, so we analyzed relapses and chemotherapy-resistant rhabdomyosarcoma tumors from pediatric sufferers and located that that they had notably excessive ranges of CXCR4 expression. Furthermore, in assays in vitro, anti-CXCR4 blocking antibody effectively diminished migration and invasion of alveolar rhabdomyosarcoma RH30 cells.
Then again, activated and expanded pure killer (NKAE) cell remedy confirmed excessive cytotoxicity towards sarcoma cells in vitro and utterly inhibited RH30 tumor implantation in vivo. Solely the mix of MDX1338 and NKAE therapies utterly suppressed metastasis in mice.
On this examine, we suggest a novel therapeutic method primarily based on anti-CXCR4 blocking antibody together with NKAE cell remedy to stop rhabdomyosarcoma tumor implantation and lung metastasis. These outcomes present the primary proof for the efficacy of this mixed immunotherapy for stopping sarcoma illness dissemination.
Anti-CXCR4 Single-Chain Variable Fragment Antibodies Have Anti-Tumor Activity

CXCR4 in human osteosarcoma malignant development. The response of osteosarcoma cell traces to the totally human CXCR4 antibody MDX1338.

Osteosarcoma (OS) is probably the most frequent main malignant tumour of bone and metastases happen in 30% of circumstances, the 5-year survival price is 25-30%. Though pre- and post-operative chemotherapy has improved prognosis in osteosarcoma (OS), excessive toxicity and pure and bought drug-resistance are the primary reason behind therapy failure.
The identification of latest predictive and therapeutic biomarkers could improve drug sensitivity and higher management localized and metastatic illness. By the proof that CXCR4 receptor by binding its ligand CXCL12 prompts downstream crucial endpoints for tumour malignancy, we first studied human OS development correlating CXCR4 expression in OS biopsy with affected person scientific information.
By Actual-time PCR and immunoistochemistry we discovered that top ranges of CXCR4 gene and protein expression considerably correlated with OS development, emphasizing the position of CXCR4/CXCL12 axis in tumour prognosis. This was supported by univariate analyses that confirmed the next chance of native and/or systemic relapse in OS sufferers with a excessive CXCR4 gene expression and a big improve of metastasis danger related to an growing rating of CXCR4 protein staining depth.
Secondarily, to check the position of CXCR4 as a goal for brand spanking new therapeutic methods, we evaluated the response of OS cells to the totally human CXCR4 antibody, MDX1338. Within the examine we additionally included AMD3100, probably the most studied CXCR4 antagonist. In CXCR4-positive OS cells cultured in CXCL12-rich BM-MCS-CM (bone marrow-derived mesenchymal stem conditioned medium), a lower of cell proliferation as much as 30%-40% of management was seen after drug publicity.
Nonetheless, a rise of apoptosis was seen in p53-positive U2OS and 143B after CXCR4 inhibitor incubation, whereas no modifications have been seen in handled SAOS-2 cells which additionally current a special labeling profile. The position of p53 in apoptotic response to CXCR4 inhibitors was confirmed by p53 silencing in U2OS cell line.

CXCR4 Antibody
24002-100ul 100ul
EUR 468

CXCR4 Antibody
24003 100ul
EUR 479

CXCR4 Antibody
24003-100ul 100ul
EUR 468

CXCR4 Antibody
1012-002mg 0.02 mg
EUR 206.18
Description: CXCR4, a G-protein coupled receptor (GPCR) with seven transmembrane domains, is a CXC chemokine receptor specific for stromal-derived-factor-1 (SDF-1 or CXCL12). CXCR4 was initially discovered as one of the co-receptors for HIV entry into CD4+ T cells (1). Blocking CXCR4 could be potentially used as novel therapeutics for HIV treatment.

CXCR4 signaling plays an important role in the migration, proliferation and quiescence of hematopoietic stem cell and their retention within the bone marrow, where it has high levels of SDF-1/CXCL12(2). It has been demonstrated that CXCR4 signaling mediates CD20 up-regulation on B cells (3).

CXCR4 is highly expressed in more than 23 types of cancer, including breast cancer, ovarian cancer, melanoma, and prostate cancer, while there is very less or no expression of CXCR4 in healthy tissues. CXCR4 expression in cancer cells has been reported to be associated with tumor survival, growth and metastasis in tissues with high levels of SDF-1/CXCL12, such as lungs, liver and bone marrow (4,5).

CXCR4 has been shown to regulate neuronal migration, cell positioning and axon wiring (6,7). CXCR4 mutant mice displayed aberrant neuronal distribution, which implicates the role in neuronal disorders such as epilepsy. CXCR4 is also involved in WHIM syndrome (8). WHIM mutations in CXCR4 were recently found in patients with Waldenstrom's macroglobulinemia, and these mutations are correlated to clinical resistance to ibrutinib (9,10).

CXCR4 Antibody
1012-01mg 0.1 mg
EUR 523.7
Description: CXCR4, a G-protein coupled receptor (GPCR) with seven transmembrane domains, is a CXC chemokine receptor specific for stromal-derived-factor-1 (SDF-1 or CXCL12). CXCR4 was initially discovered as one of the co-receptors for HIV entry into CD4+ T cells (1). Blocking CXCR4 could be potentially used as novel therapeutics for HIV treatment.

CXCR4 signaling plays an important role in the migration, proliferation and quiescence of hematopoietic stem cell and their retention within the bone marrow, where it has high levels of SDF-1/CXCL12(2). It has been demonstrated that CXCR4 signaling mediates CD20 up-regulation on B cells (3).

CXCR4 is highly expressed in more than 23 types of cancer, including breast cancer, ovarian cancer, melanoma, and prostate cancer, while there is very less or no expression of CXCR4 in healthy tissues. CXCR4 expression in cancer cells has been reported to be associated with tumor survival, growth and metastasis in tissues with high levels of SDF-1/CXCL12, such as lungs, liver and bone marrow (4,5).

CXCR4 has been shown to regulate neuronal migration, cell positioning and axon wiring (6,7). CXCR4 mutant mice displayed aberrant neuronal distribution, which implicates the role in neuronal disorders such as epilepsy. CXCR4 is also involved in WHIM syndrome (8). WHIM mutations in CXCR4 were recently found in patients with Waldenstrom's macroglobulinemia, and these mutations are correlated to clinical resistance to ibrutinib (9,10).

CXCR4 Antibody
1009-002mg 0.02 mg
EUR 206.18
Description: CXCR4, a G-protein coupled receptor (GPCR) with seven transmembrane domains, is a CXC chemokine receptor specific for stromal-derived-factor-1 (SDF-1 or CXCL12). CXCR4 was initially discovered as one of the co-receptors for HIV entry into CD4+ T cells (1). Blocking CXCR4 could be potentially used as novel therapeutics for HIV treatment.

CXCR4 signaling plays an important role in the migration, proliferation and quiescence of hematopoietic stem cell and their retention within the bone marrow, where it has high levels of SDF-1/CXCL12(2). It has been demonstrated that CXCR4 signaling mediates CD20 up-regulation on B cells (3).

CXCR4 is highly expressed in more than 23 types of cancer, including breast cancer, ovarian cancer, melanoma, and prostate cancer, while there is very less or no expression of CXCR4 in healthy tissues. CXCR4 expression in cancer cells has been reported to be associated with tumor survival, growth and metastasis in tissues with high levels of SDF-1/CXCL12, such as lungs, liver and bone marrow (4,5).

CXCR4 has been shown to regulate neuronal migration, cell positioning and axon wiring (6,7). CXCR4 mutant mice displayed aberrant neuronal distribution, which implicates the role in neuronal disorders such as epilepsy. CXCR4 is also involved in WHIM syndrome (8). WHIM mutations in CXCR4 were recently found in patients with Waldenstrom's macroglobulinemia, and these mutations are correlated to clinical resistance to ibrutinib (9,10).

CXCR4 Antibody
1009-01mg 0.1 mg
EUR 523.7
Description: CXCR4, a G-protein coupled receptor (GPCR) with seven transmembrane domains, is a CXC chemokine receptor specific for stromal-derived-factor-1 (SDF-1 or CXCL12). CXCR4 was initially discovered as one of the co-receptors for HIV entry into CD4+ T cells (1). Blocking CXCR4 could be potentially used as novel therapeutics for HIV treatment.

CXCR4 signaling plays an important role in the migration, proliferation and quiescence of hematopoietic stem cell and their retention within the bone marrow, where it has high levels of SDF-1/CXCL12(2). It has been demonstrated that CXCR4 signaling mediates CD20 up-regulation on B cells (3).

CXCR4 is highly expressed in more than 23 types of cancer, including breast cancer, ovarian cancer, melanoma, and prostate cancer, while there is very less or no expression of CXCR4 in healthy tissues. CXCR4 expression in cancer cells has been reported to be associated with tumor survival, growth and metastasis in tissues with high levels of SDF-1/CXCL12, such as lungs, liver and bone marrow (4,5).

CXCR4 has been shown to regulate neuronal migration, cell positioning and axon wiring (6,7). CXCR4 mutant mice displayed aberrant neuronal distribution, which implicates the role in neuronal disorders such as epilepsy. CXCR4 is also involved in WHIM syndrome (8). WHIM mutations in CXCR4 were recently found in patients with Waldenstrom's macroglobulinemia, and these mutations are correlated to clinical resistance to ibrutinib (9,10).

CXCR4 Antibody
1-CSB-PA250029
  • Ask for price
  • Ask for price
  • 50ul
  • 100ul
Description: A polyclonal antibody against CXCR4. Recognizes CXCR4 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:25-1:100

CXCR4 Antibody
1-CSB-PA263860
  • Ask for price
  • Ask for price
  • 50ul
  • 100ul
Description: A polyclonal antibody against CXCR4. Recognizes CXCR4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200

CXCR4 Antibody
1-CSB-PA099227
  • Ask for price
  • Ask for price
  • 50ul
  • 100ul
Description: A polyclonal antibody against CXCR4. Recognizes CXCR4 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:25-1:100

CXCR4 Antibody
1-CSB-PA002588
  • Ask for price
  • Ask for price
  • 50ug
  • 100ug
Description: A polyclonal antibody against CXCR4. Recognizes CXCR4 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IF, ELISA;WB:1/500-1/2000.IF:1/200-1/1000.ELISA:1/40000

CXCR4 Antibody
1-CSB-PA006254GA01HU
  • Ask for price
  • Ask for price
  • 50ul
  • 150ul
Description: A polyclonal antibody against CXCR4. Recognizes CXCR4 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB

CXCR4 Antibody
1-CSB-PA006254YA01HU
  • Ask for price
  • Ask for price
  • 50ug
  • 100ug
Description: A polyclonal antibody against CXCR4. Recognizes CXCR4 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF; Recommended dilution: WB:1:500-1:2000, IHC:1:20-1:200, IF:1:50-1:200

CXCR4 Antibody
abx140472-100tests 100 tests
EUR 577.2

CXCR4 Antibody
AF7829 200ul
EUR 540

CXCR4 Antibody
AF7829-100ul 100ul
EUR 210
Description: WB,ELISA(peptide)

CXCR4 Antibody
AF7829-200ul 200ul
EUR 270
Description: WB,ELISA(peptide)

CXCR4 Antibody
AF7829-50ul 50ul
EUR 150
Description: WB,ELISA(peptide)

CXCR4 Antibody
DF8046 200ul
EUR 420

CXCR4 Antibody
DF8046-100ul 100ul
EUR 168
Description: WB,IF/ICC,ELISA(peptide)

CXCR4 Antibody
DF8046-200ul 200ul
EUR 210
Description: WB,IF/ICC,ELISA(peptide)

CXCR4 Antibody
AF5279 200ul
EUR 420

CXCR4 Antibody
AF5279-100ul 100ul
EUR 168
Description: WB,IHC,IF/ICC,ELISA(peptide)

CXCR4 Antibody
AF5279-200ul 200ul
EUR 210
Description: WB,IHC,IF/ICC,ELISA(peptide)

CXCR4 Antibody
E036326 100μg/100μl
EUR 255
Description: Available in various conjugation types.

CXCR4 Antibody
AF6641 100ul
EUR 420

CXCR4 Antibody
AF6641-100ul 100ul
EUR 168
Description: WB,ELISA(peptide)

CXCR4 Antibody
AF6641-200ul 200ul
EUR 210
Description: WB,ELISA(peptide)

CXCR4 Antibody
AF6642 100ul
EUR 420

CXCR4 Antibody
AF6642-100ul 100ul
EUR 168
Description: ELISA(peptide)

CXCR4 Antibody
AF6642-200ul 200ul
EUR 210
Description: ELISA(peptide)

CXCR4 Antibody
C40188-100ul 100μl
EUR 217
Description: CXCR4 Rabbit Polyclonal Antibody

CXCR4 Antibody
C40188-50ul 50μl
EUR 143.5
Description: CXCR4 Rabbit Polyclonal Antibody

CXCR4 Antibody
1-CSB-PA996565
  • Ask for price
  • Ask for price
  • 50ul
  • 100ul
Description: A polyclonal antibody against CXCR4. Recognizes CXCR4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:2000, IHC:1:25-1:100

CXCR4 Antibody
CAC07015-100ug 100ug
EUR 314

CXCR4 Antibody
CAC07015-50ug 50ug
EUR 199.2

CXCR4 Antibody
E11-064G 100μg
EUR 225
Description: Available in various conjugation types.
Our information counsel that the response to anti-CXCR4 brokers might be influenced by the genetic background and labeling profile which induces a special cross-talk between tumour cells and atmosphere. The delay in cell cycle development related to elevated apoptosis might sensitize p53-positive cells to standard remedy and in vivo preclinical experiments are on going with the intention to counsel new mixed goal therapies in human OS.
Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post

gag assay, Spontaneous Mutations in HIV-1 Gag, Protease, RT p66 in the First Replication Cycle and How They Appear: Insights from an In Vitro Assay on Mutation Rates and Types

Spontaneous Mutations in HIV-1 Gag, Protease, RT p66 in the First Replication Cycle and How They Appear: Insights from an In Vitro Assay on Mutation Rates and TypesSpontaneous Mutations in HIV-1 Gag, Protease, RT p66 in the First Replication Cycle and How They Appear: Insights from an In Vitro Assay on Mutation Rates and Types

Whereas drug resistant mutations in HIV-1 are largely credited to its error susceptible HIV-1 RT, the time level within the an infection cycle that these mutations can come up and

READ MOREREAD MORE